Adoptive T Cell Therapy Is Poised To Change
The Prognosis Of Advanced Cancer

Verik is committed to keeping the issues likely to impact successful commercialization front and center through the sharing of information and knowledge.

Meetings and Presentations

Joe Laning, VP of Molecular Immunology, attended Cambridge Healthtech’s Immuno-Oncology Summit. Boston, MA August 29-30, 2017

Poster presentation: Achieving Cost-Effective, Large-Scale Manufacture of Personalized CAR/TCR-based Therapies

(link to pdf)

 

Nancy Parenteau, Verik’s President and CSO, and Susan Sullivan, VP of Operations, will be attending the Hanson-Wade CAR-TCR Summit 2017, Boston, MA, September 6-7, 2017

 

© 2017 Verik Bio, Inc
website design by Alice Sargent